Zobrazeno 1 - 10
of 1 891
pro vyhledávání: '"Trough Concentration"'
Autor:
Hanzhen Zhao, Lian Tang, Zhiwei Zhuang, Ying Zhang, Jingjing Li, Lufen Duan, Lu Shi, Chenqi Zhu, Jian Lu, Yunlong Yuan, Qian Zhang, Yanxia Yu, Jinhui Xu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract A nomogram to estimate the risk of linezolid-induced thrombocytopenia in patients with renal impairment is not available. The aim of the study is to develop a nomogram for predicting linezolid-induced thrombocytopenia in patients with renal
Externí odkaz:
https://doaj.org/article/7f2fb51bb68b403e8346a285689f0e8e
Autor:
Sandra Abdul Massih, Mohamed G. Atta, Chloe L. Thio, Jeffrey A. Tornheim, Edward J. Fuchs, Rahul P. Bakshi, Mark A. Marzinke, Craig W. Hendrix, Ethel D. Weld
Publikováno v:
AIDS Research and Therapy, Vol 21, Iss 1, Pp 1-7 (2024)
Abstract Introduction Peritoneal dialysis (PD) is an effective renal replacement modality in people with HIV (PWH) with end-stage kidney disease (ESKD), particularly those with residual kidney function. Data on pharmacokinetics (PK) of antiretroviral
Externí odkaz:
https://doaj.org/article/59cf5db24a5e45429f5b55b2e62a0c5b
Autor:
Hiroki Yagura, Dai Watanabe, Takao Nakauchi, Hiroyuki Kushida, Kazuyuki Hirota, Yasuharu Nishida, Munehiro Yoshino, Tomoko Uehira, Takuma Shirasaka
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Background The relationship between plasma tenofovir (TFV) concentration at the beginning of tenofovir disoproxil fumarate (TDF) administration and the development of renal dysfunction during long-term administration of TDF has not been demo
Externí odkaz:
https://doaj.org/article/68764e78eae34d859cec735488606237
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Vancomycin-associated acute kidney injury (VA-AKI) is the most clinically relevant side effect of vancomycin. The objective of this study was to investigate the association between VTC and VA-AKI as well as 30-day mortality in cri
Externí odkaz:
https://doaj.org/article/e0fe811565ec41da907e6a9965207a2e
Publikováno v:
Renal Failure, Vol 46, Iss 1 (2024)
Objective To explore independent influencing factors for clinical efficacy of roxadustat in hemodialysis patients.Methods Hemodialysis patients treated with roxadustat were enrolled. The plasma trough concentrations of roxadustat were measured using
Externí odkaz:
https://doaj.org/article/806249233330466e840274b928e5d83b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jieqiong Liu, Xuan Zhang, Gang Liang, Jianping Zhu, Yi Yang, Ying Zheng, Yun Han, Lingyan Yu, Yuhua Zhao, Zhenwei Yu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe latest published therapeutic drug monitoring (TDM) guidelines for vancomycin recommend changing trough-based monitoring to area under the concentration-to-time curve (AUC)-based monitoring. This study aimed to evaluate the implementatio
Externí odkaz:
https://doaj.org/article/5875f23b85df4f62976ebb189d9c5315
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundVoriconazole is primarily metabolized by CYP2C19 and CYP3A4. Drug interactions that affect this pathway can alter its plasma exposures, resulting in untargeted voriconazole concentrations.Case summaryIn this case report, we describe the cas
Externí odkaz:
https://doaj.org/article/434e741e50a24537875bcc18444c479d
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Aim Patients with advanced gastrointestinal stromal tumors (GISTs) exhibiting an imatinib plasma trough concentration (IM Cmin) under 1100 ng/ml may show a reduced drug response rate, leading to the suggestion of monitoring for IM Cmin. Cons
Externí odkaz:
https://doaj.org/article/d4cea1f460844702854808d7214004d5
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009